Search Results for: covid-19
Articles
uniQure Announces Enrollment of Next Two Patients in Phase 1/2 Clinical Trial October 14, 2020
uniQure N.V. recently announced that two additional patient procedures have been completed in the Phase 1/2 clinical trial of AMT-130...WEBINAR SERIES ALERT - Learn About Complex Parenteral Drug Delivery From Evonik Industry Experts - Free Oct-Nov Webinar Series October 14, 2020
As a global CDMO leader for advanced drug delivery, Evonik invites you to join us for a webinar series on parenteral drug delivery. More than a dozen technical experts from Evonik will review….
Scientific Management of Pharmaceutical Container Closure & Delivery Device Compatibility October 13, 2020
Diane Paskiet says the relationship between pharmaceutical products and CC/DD is best managed through a rich science-based approach that factors in potential risk and is adapted early in the development process.
Noble & Aptar Pharma Connected Medical Device Solution for Disease Management Adherence & Onboarding Patients October 7, 2020
Noble and Aptar Pharma recently announced the launch of AdhereIT - a connected, intuitive, and user-friendly onboarding solution for the...Evaxion Biotech Launches New AI Powered Platform to Enable Faster Response to Emerging Viral Pandemics October 7, 2020
Evaxion Biotech recently announced it has received approximately $800,000 in funding from Innovation Fund Denmark for the development of its...Recipharm Signs Agreement With Arcturus Therapeutics to Support the Manufacture of LUNAR-COV19 (ARCT-021) Vaccine Candidate October 7, 2020
Recipharm has recently entered into an agreement with Arcturus Therapeutics, a leading US-based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and….
CDMO CASE STUDY - AJILITY: Streamlining Drug Product Manufacturing October 1, 2020
Dustin Campbell says the AJILITY platform takes the burden off clients and allows his company to drive, manage, and support their drug product manufacturing, maximizing speed and success, while prioritizing these programs are driven to completion.
EXECUTIVE INTERVIEW - Immunic Therapeutics: Developing Next-Generation Oral Drugs in Chronic Inflammatory, Autoimmune & Infectious Diseases October 1, 2020
Daniel Vitt, PhD, Immunic’s Chief Executive Officer and President, discusses his company’s pipeline of selective, small molecule therapies aimed at treating chronic inflammatory and autoimmune diseases, and its recent progress.
Veru Completes Enrollment of Phase 2 Clinical Trial of Novel Oral Drug September 29, 2020
Veru Inc. recently announced it has fully enrolled its Phase 2 clinical study of VERU-111, its novel, oral, alpha and...Orgenesis Announces Agreement to Acquire Koligo Therapeutics September 29, 2020
Orgenesis Inc. and Koligo Therapeutics, Inc. recently announced the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected completion….
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation September 29, 2020
Mereo BioPharma Group plc recently announced that the US FDA has granted Rare Pediatric Disease designation to setrusumab for the...TriNetX Acquired by Carlyle Group to Help Advance Health Research Optimization September 22, 2020
TriNetX recently announced global investment firm The Carlyle Group has made a strategic growth investment and will acquire a majority...ARCA biopharma Announces Submission of IND Application September 22, 2020
ARCA biopharma, Inc. recently announced it has submitted an Investigational New Drug (IND) application with the US FDA under the Coronavirus...Arctoris & Syntekabio Form Drug Discovery Research Partnership September 15, 2020
Arctoris has recently signed a Memorandum of Understanding with listed Korean company Syntekabio, Inc. to collaborate on drug discovery efforts....Fortress Biotech Announces Initiation of Phase 3 Studies September 15, 2020
Fortress Biotech, Inc. recently announced that Caelum Biosciences, Inc., in collaboration with Alexion Pharmaceuticals, Inc., initiated the Cardiac Amyloid Reaching...Catalent to be Added to S&P 500 Index September 15, 2020
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 September 9, 2020
RedHill Biopharma Ltd. recently announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral...Liminal BioSciences Announces Resubmission of Biologics License Application September 9, 2020
Liminal BioSciences Inc. recently announced the company, through its US subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the...Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study September 9, 2020
Cynata Therapeutics Limited recently announced positive efficacy data from a study of its induced pluripotent stem cell (iPSC)-derived Cymerus mesenchymal...Spero Therapeutics Announces Positive Topline Results From its Phase 3 ADAPT-PO Clinical Trial September 9, 2020
Spero Therapeutics, Inc. recently announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero’s oral antibiotic...
